Guangdong Zhongsheng Pharmaceutical Co., Ltd.

SZSE:002317 Rapport sur les actions

Capitalisation boursière : CN¥10.0b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Guangdong Zhongsheng Pharmaceutical Croissance future

Future contrôle des critères 4/6

Guangdong Zhongsheng Pharmaceutical devrait augmenter ses bénéfices et son chiffre d'affaires de 34.7% et de 15.7% par an respectivement. Le BPA devrait croître de de 34.4% par an. Le rendement des capitaux propres devrait être 9.4% dans 3 ans.

Informations clés

34.7%

Taux de croissance des bénéfices

34.4%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices18.8%
Taux de croissance des recettes15.7%
Rendement futur des capitaux propres9.4%
Couverture par les analystes

Low

Dernière mise à jour14 Aug 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

These 4 Measures Indicate That Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Is Using Debt Reasonably Well

Jul 12
These 4 Measures Indicate That Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Is Using Debt Reasonably Well

Guangdong Zhongsheng Pharmaceutical Co., Ltd.'s (SZSE:002317) P/E Is On The Mark

Jun 18
Guangdong Zhongsheng Pharmaceutical Co., Ltd.'s (SZSE:002317) P/E Is On The Mark

Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Has Affirmed Its Dividend Of CN¥0.20

May 20
Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Has Affirmed Its Dividend Of CN¥0.20

We Think You Can Look Beyond Guangdong Zhongsheng Pharmaceutical's (SZSE:002317) Lackluster Earnings

Apr 29
We Think You Can Look Beyond Guangdong Zhongsheng Pharmaceutical's (SZSE:002317) Lackluster Earnings

Does Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Have A Healthy Balance Sheet?

Mar 18
Does Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Have A Healthy Balance Sheet?

Guangdong Zhongsheng Pharmaceutical Co., Ltd.'s (SZSE:002317) Shares Climb 29% But Its Business Is Yet to Catch Up

Feb 29
Guangdong Zhongsheng Pharmaceutical Co., Ltd.'s (SZSE:002317) Shares Climb 29% But Its Business Is Yet to Catch Up

Prévisions de croissance des bénéfices et des revenus

SZSE:002317 - Estimations futures des analystes et données financières antérieures (CNY Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20263,888491N/A3581
12/31/20253,399428N/A3242
12/31/20242,947307N/A1031
3/31/20242,505175-36257N/A
12/31/20232,611263-172191N/A
9/30/20232,756353-446-21N/A
6/30/20232,833328-447-37N/A
3/31/20232,747387-466-108N/A
1/1/20232,676322-20563N/A
9/30/20222,597213241441N/A
6/30/20222,545192411617N/A
3/31/20222,489295400598N/A
1/1/20222,429278409623N/A
9/30/20212,409-414-97100N/A
6/30/20212,321-330-15013N/A
3/31/20212,122-423-27126N/A
12/31/20201,896-427-16139N/A
9/30/20201,923251181323N/A
6/30/20202,010207189336N/A
3/31/20202,30724495240N/A
12/31/20192,532318123251N/A
9/30/20192,538454220356N/A
6/30/20192,474464320455N/A
3/31/20192,378439325449N/A
12/31/20182,362436183327N/A
9/30/20182,306455229381N/A
6/30/20182,197447120274N/A
3/31/20182,12543237192N/A
12/31/20171,964420N/A370N/A
9/30/20171,855427N/A223N/A
6/30/20171,837439N/A230N/A
3/31/20171,713432N/A297N/A
12/31/20161,692414N/A338N/A
9/30/20161,673380N/A274N/A
6/30/20161,640371N/A351N/A
3/31/20161,668325N/A334N/A
12/31/20151,578297N/A192N/A
9/30/20151,494276N/A356N/A
6/30/20151,433257N/A219N/A
3/31/20151,367238N/A75N/A
12/31/20141,309225N/A101N/A
9/30/20141,234219N/A96N/A
6/30/20141,190211N/A97N/A
3/31/20141,117194N/A144N/A
12/31/20131,090188N/A111N/A
9/30/20131,048187N/A95N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: 002317's forecast earnings growth (34.7% per year) is above the savings rate (2.9%).

Bénéfices vs marché: 002317's earnings (34.7% per year) are forecast to grow faster than the CN market (21.9% per year).

Croissance élevée des bénéfices: 002317's earnings are expected to grow significantly over the next 3 years.

Chiffre d'affaires vs marché: 002317's revenue (15.7% per year) is forecast to grow faster than the CN market (13.4% per year).

Croissance élevée des revenus: 002317's revenue (15.7% per year) is forecast to grow slower than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de 002317 devrait être faible dans 3 ans ( 9.4 %).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y